DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma
In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Meletios Dimopoulos, MD, a professor and chair of the Department of Clinical Therapeutics at the National and Kopodistrian University of Athens School of Medicine in Athens, Greece. They talk about a recent paper co-authored by Dr. Dimopoulos: “Belantamab Mafodotin, Pomalidomide (PA), and Dexamethasone in Multiple Myeloma.”